Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients.
about
Networks of fibers and factors: regulation of capsule formation in Cryptococcus neoformansCryptococcus and Phagocytes: Complex Interactions that Influence Disease OutcomeFighting the Monster: Applying the Host Damage Framework to Human Central Nervous System InfectionsNew autoantibody detection technologies yield novel insights into autoimmune diseaseCryptococcus gattii infectionsImmunoregulation in Fungal DiseasesThe spectrum of fungi that infects humansPopulation Genetic Analysis Reveals a High Genetic Diversity in the Brazilian Cryptococcus gattii VGII Population and Shifts the Global Origin from the Amazon Rainforest to the Semi-arid Desert in the Northeast of BrazilManagement of Cryptococcus gattii meningoencephalitis.Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis.Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis.Cryptococcosis diagnosis and treatment: What do we know nowMononuclear phagocyte-mediated antifungal immunity: the role of chemotactic receptors and ligands.Paradoxical Immune Responses in Non-HIV Cryptococcal MeningitisCryptococcal heat shock protein 70 homolog Ssa1 contributes to pulmonary expansion of Cryptococcus neoformans during the afferent phase of the immune response by promoting macrophage M2 polarizationRising to the challenge of multiple Cryptococcus species and the diseases they cause.Anti-cytokine autoantibodies in postherpetic neuralgia.Cryptococcus gattii molecular type VGII infection associated with lung disease in a goatImmune correlates of HIV-associated cryptococcal meningitisPost-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis.Genetic Susceptibility to Fungal Infections: What is in the Genes?Cryptococcus: from environmental saprophyte to global pathogen.Is Cryptococcus gattii a Primary Pathogen?Local GM-CSF-Dependent Differentiation and Activation of Pulmonary Dendritic Cells and Macrophages Protect against Progressive Cryptococcal Lung Infection in Mice.Immunity to Cryptococcus neoformans and C. gattii during cryptococcosisRole of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.What makes Cryptococcus gattii a pathogen?Cryptococcal therapies and drug targets: the old, the new and the promising.Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults.Pulmonary Cryptococcosis in the Immunocompetent Patient-Many Questions, Some Answers.Immunization with Antigen-Pulsed Dendritic Cells Against Highly Virulent Cryptococcus gattii Infection: Analysis of Cytokine-Producing T Cells.Disseminated Cryptococcosis Due to Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in the Absence of Pulmonary Alveolar Proteinosis.Innate Immune Responses to Cryptococcus.Cryptococcus gattii Meningitis Complicated by Listeria monocytogenes Infection.Autoantibodies to Granulocyte-Macrophage Colony-Stimulating Factor Associated With Severe and Unusual Manifestations of Cryptococcus gattii Infections.Modulating host immune responses to fight invasive fungal infections.Induction of Broad-Spectrum Protective Immunity against Disparate Cryptococcus Serotypes.Cryptococcus: Shedding New Light on an Inveterate Yeast.Adaptive Immunity to Cryptococcus neoformans Infections.Masking the Pathogen: Evolutionary Strategies of Fungi and Their Bacterial Counterparts.
P2860
Q26741771-DC5F31A5-4640-436F-B547-62B183568AA7Q26767978-A367C79E-AEA1-4BEE-B74C-E3B29070681FQ26774211-D1D1072C-D0CC-4DC1-86AA-4FA1548923C4Q27000173-ED4F3814-8641-4BE0-A44E-C4FC707284F0Q27002687-86BAA8BE-F409-47D0-B415-C99E583C19F7Q28074776-24E49737-0625-475B-B951-D8D5195FB5C7Q28652321-6E2B56DC-F683-4AC5-8968-02351A95F77CQ28830168-2DE17173-687C-4B41-8BA1-432E4DFC914DQ30873978-927F0B6A-30D0-4293-80FB-799F6ABBF678Q33790656-A6ABB303-7380-4149-946B-ECFFC4DF0E0AQ35197274-2AC59309-7BE1-47F7-B7E9-F66F44328467Q35395169-19275C57-4E76-4A0A-876A-7C5ED63EB5CAQ35602489-81D96211-BBCE-471E-B99F-50948358C55BQ35645083-0819FF0E-47AF-4A6E-A937-CA73242F3201Q35691068-24A21258-E1C3-4D9E-B127-C8FA76326D85Q35706177-97E3E9D2-791A-45B4-ABF1-FC49CCAF56C3Q36198740-E7B1847A-B3A7-474C-B4BA-26607455C881Q36273382-39BFB5D4-F9A4-48AD-ACA5-85474BE3F2B8Q36320051-461F5F84-D376-4351-87AE-C3C47B5478E0Q36781260-665E8211-08A9-4412-9FC8-1C56334EA84CQ37183884-8A198773-3A3A-4937-8184-BCD7C3133534Q37250158-9BA011FD-2F56-4602-BDEA-DA803FBC0A1FQ37375089-75EC879A-D2D5-4B44-8217-ECF3F7BBBD65Q38274984-522BF2DC-86D5-495B-BF34-90C184008B80Q38286732-6A35DF1E-BEF5-48DB-A783-05CD5C03FC74Q38644509-F828F554-A16A-4BC6-8660-F4F2FC6A0985Q38650835-71263D39-2453-43D3-AD60-F12ADE0B0954Q38779568-FAC77C5E-775B-4649-9D87-1F9FA8D654C7Q39067727-C88164C2-3EE0-44AB-8492-ECA7B2A88764Q39322243-BE8665E2-67B9-4198-97A1-220C2A3701BBQ40171425-E62229FD-191A-4AF8-9DFB-8043C7CE11E7Q40396098-57EACC0A-3867-46A2-B4C1-A931AB1EFC26Q41721935-7F8917D3-EB87-42A3-99B4-44E3E52E70B6Q42339901-1C626AC5-0DBA-4236-8AAC-92F92F8C8E92Q44911201-5A7E10E7-957E-4373-9535-272FC25F4198Q46673081-3E5D372D-54BF-40EB-AE4A-53FD22944BCEQ47118458-0C8E040E-D0EE-4185-AACD-1FF93964157CQ47548230-B03FC06D-69EA-4FCE-8B28-E762CE534D47Q49188733-C7201CCC-1D35-4FE5-B3F1-2316422549DBQ49410181-83C78EAD-F695-4E40-9C4F-1F4B3F165DF1
P2860
Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@en
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@nl
type
label
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@en
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@nl
prefLabel
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@en
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@nl
P2093
P2860
P921
P356
P1433
P1476
Anti-granulocyte-macrophage co ...... wise immunocompetent patients.
@en
P2093
Jianghan Chen
John E Bennett
Kyung J Kwon-Chung
Lindsey B Rosen
Sarah K Browne
Sharon C-A Chen
Steven M Holland
Tomomi Saijo
P2860
P304
P356
10.1128/MBIO.00912-14
P577
2014-03-18T00:00:00Z